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Abstract 
Cadmium- and lead-based quantum dots are normally coated for biological applications, because their 
degradation may result in the release of toxic heavy metal ions. Here, we synthesize silicon quantum 
dots that are expected to biodegrade to non-toxic products. A chitosan coating is used to render the 
silicon quantum dots stable in storage conditions and biodegradable at physiological conditions. The 
applications of these particles are demonstrated in cellular imaging with single and two-photon 
excitation. These results open the door for a new generation of silicon quantum dots that may have a 
wide variety of applications derived from the flexibility of chitosan. 
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Introduction 
The discovery and investigation of light-emitting semiconductor nanocrystals (quantum dots) has led 
to significant demonstrations of their potential to advance biological research.
1-2
 However, achieving 
efficient imaging in a target cell population or tissue without causing any quantum dot-associated 
toxicity is critical for expanding their role as imaging agents. Important efforts have already been 
focused on reducing the toxicity of heavy metal-based quantum dots for biological applications.
3-4
 
Among them, coating cadmium-based nanoparticles with a ZnS shell has been shown to reduce the 
toxicity of particles that enter systemic circulation. Several years ago, it was widely accepted that heavy-
metal-based quantum dots showed promise for future clinical applications.
5-6
 At the time, the focus was 
on quantum dots’ bright emission, multiplex imaging capabilities, broad excitation spectra, photo-
stability, and lifetime. However, the inclusion of toxic elements in these QDs has slowed their 
translation toward the clinic. While several studies have used of Cd-based QDs in animals with no 
apparent toxicity
4
, use of heavy metals remains undesirable in the rational design of nanoparticle 
imaging agents because: (1) the toxic reputation of bulk and elemental cadmium creates resistance to 
Cd-based quantum dots being accepted as non-toxic
3
 (2) extensive studies will be needed to evaluate 
multiple potential routes of Cd-based QD toxicity to alleviate concerns,
4
 and (3) although 
biodegradation is desirable for most imaging agents, approaches to address toxicity of Cd-based QDs 
generally aim to avoid biodegradation because of the resulting release of Cd ions.
7
 The need for 
inherently non-toxic components for quantum dots has partially motivated the development of silicon 
quantum dots (SiQDs).
8-12
 However, despite recent progress in development of SiQDs for bioimaging, 
further advances are required, including development of optimal encapsulation strategies, increasing its 
quantum yield, and creating nanoconstructs that exploit its biodegradability. Additionally, physiological 
factors affecting the performance and degradation of silicon nanoparticles are not yet well understood. 
Nevertheless, there are important biological principles that can guide the design of a desirable silicon 
quantum dots nanostructure. With these principles in mind, advancements have been made using SiQDs 
for biological applications. Sailor’s group recently developed biodegradable porous silicon 
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nanostructures and demonstrated tumor imaging with them.
13
 Although free standing silicon is expected 
to degrade by the same routes as porous silicon, its surface chemistry and structure are different enough 
for it to be considered a different nanomaterial. Kauzlarich’s group has developed Mn-doped SiQDs for 
magnetic resonance imaging, demonstrated in macrophages.
11
 Tilley’s group has demonstrated that 
silicon quantum dots are 10 times less toxic than Cd-based quantum dots and used them for cellular 
imaging
14
. We previously have designed new types of SiQD-based nanoconstructs that improved the 
quality, and options available for silicon based imaging agents.
9
 The systems are PEGylated 
phospholipid micelle encapsulated silicon quantum dots (MSiQDs) that are useful for cancer 
applications such as tumor targeting, sentinel lymphnode mapping and multiplex imaging.
15
 The 
MSiQDs were designed to make the SiQDs more stable in vivo. In them, the PEG brush hinders 
protein/enzyme adsorption while the SiQDs remain in the hydrophobic interior of the micelles. That 
approach provides very stable particles whose in vivo luminescence remains visible even after one 
month. However, for many applications, biodegradation after a shorter time would be preferable. 
Chitosan, a naturally biodegradable, biocompatible polymer has been extensively used in biological 
investigations,
16
 including nucleic acid transfection,
17-18
 protein delivery,
19
 drug delivery,
20
 and quantum 
dot encapsulation.
21-22
 These prior studies of chitosan-coated quantum dots showed promise for 
biological imaging, however they used cadmium based quantum dots. Here, we report a biodegradable 
chitosan-silicon nanocomplex (CSiQDs) for imaging applications. We chose 75-85% deacetylated low 
molecular weight chitosan to make a reasonably sized nanoparticles and provide adequate stabilization 
with a positive charge. Undecylenic acid was used to functionalize the SiQDs because of its 
biocompatibility, it carboxyl termination and the photoluminescence stabilization it provides for SiQDs 
when compared to shorter chain carboxylic acids
23-24
. Figure 1 schematically depicts the hydrosilylation 
reaction that creates the Si-C linkage and the subsequent encapsulation in chitosan. 
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Figure 1. Schematic illustration of hydrosilylation reaction of undecylenic acid with hydrogen-
terminated SiQDs and the encapsulation of SiQDs with chitosan. SiQDs are represented by orange 
circles and chitosan is represented by the blue circle. 
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Results and Discussion 
Figure 1 schematically illustrates the functionalization of SiQDs with undecylenic acid and the 
chitosan encapsulation process. The double bond on undecylenic acid reacts with hydrogen terminated 
SiQDs to generate carboxyl terminated SiQDs. The amine group on each repeat unit of chitosan can 
coordinate with the caboxyl groups by electrostatic interaction of the partial positive charge of the amine 
groups and the partial negative charge of the caboxyl groups to form Si QD-embedded chitosan 
nanoparticles. Multiple silicon nanoparticles are trapped within each nanocomplex.  
Figure 2 presents the optical properties of Si-und and CSiQDs. The PL emission peak shifted slightly 
from 643 nm to 632 nm after the encapsulation. Surface coatings are known to affect the emission 
wavelength of light emitting nanoparticles. In particular, when silicon quantum dots are in water, the 
shift may be attributed to a slight oxidation. The FWHM remained approximately the same. FTIR was 
used to confirm the attachement of undecylenic acid to the particles indicating the presence of carboxyl 
groups on the surface of the silicon quantum dots
24
. The electrostatic binding interaction was confirmed 
by zeta potential. The surface charge of the particles coated with chitosan is 45eV when meausred in 
water. This positive charge is  attributed to the amine groups present in chitosan. Zeta potential 
measuments before coating the silicon with chitosan are not made because the particles are not soluble 
in water with the undecylenic acid coating.  
  
Figure 2. PL spectra of undecylenic acid functionalized SiQDs and CSiQDs 
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Figure 3 shows TEM images of the undecylenic acid coated SiQDs, before and after chitosan 
encapsulation, along with the hydrodynamic diameter distribution of the CSiQDs from dynamic light 
scattering (DLS). Parts (a) and (b) of Figure 3 show TEM images of undecylenic acid functionalized 
SiQDs. Although high-resolution imaging is challenging because of the relatively large organic fraction 
in the coated particles, sub-5 nm crystalline domains are visible. Parts (c) theough (e) of Figure 3 show 
TEM images of the CSiQDs. The particles are spherical in shape with an average size near 70 nm and 
significant variation in size. The mean hydrodynamic diameter of chitosan-encapsulated SiQDs in water 
near neutral pH was 180 nm, as shown in Fig. 3(f). The CSiQDs did not appear to be aggregated; their 
dispersion is stabilized by the positive charge of the chitosan.  The size is large for some biological 
applications; however, it is within the size range for some promising applications such as tumor 
targeting. 
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Figure 3. TEM images of (a, b) undecylenic acid terminated SiQDs, and (c, d, e) chitosan-encapsulated 
SiQDs. (f)The hydrodynamic diameter distribution of chitosan-encapsulated SiQDs as measured by 
DLS. The mean diameter is 180 nm. 
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Figure 4(a) shows the stability of the PL intensity as a function of solution pH. The CSiQDs showed 
excellent stability of their photoluminescence from pH 1 to 12. The PL varied by less than 10% over this 
pH range. This was unexpected because chitosan itself is normally unstable at basic conditions. At a pH 
of 13, however, the particles lost 98% of their luminescence. This wide pH range of PL stability may 
result from a synergistic relationship between chitosan and silicon nanoparticles that prevents rapid 
degradation. The stability of the PL from CSiQDs after heating to different temperatures is shown in 
Fig. 4(b). The PL decreased linearly with increasing temperature, however at the physiological 
temperature of 37
 
°C the particles maintain over 80% of their room-temperature luminescence. The 
particles partially regain their luminescence when cooled back to room temperature, indicating that ther 
may be increased non-radiative decay at hihger temperatures. Figure 4(c) confirmed the bio-
degradability of the CSiQDs. The results show the PL intensity of CSiQDs under three different 
conditions. One was held at 4 °C, the other two were incubated at 37 °C in water and PBS buffer, 
respectively. The refrigerated sample retained 96.2% of its PL intensity after three days, and the sample 
which was incubated in water maintained 86.8% of its intensity after three days. However, the PL 
intensity of the sample incubated in PBS buffer for three days was only 9.7% of its initial intensity. This 
suggests that the CSiQDs can be stored at 4 °C for a significant time while retaining their PL, but that 
when inserted into a biological system they will degrade within a few days. Particles (without the 
chitosan coating)  terminated with undecylenic acid maintain their PL in ethanol for months. 
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Figure 4. (a) The PL stability of CSiQDs vs. solution pH. (b) The PL stability of CSiQDs after heating to 
different temperatures. (c) The normalized PL intensity of CSiQDs stored under different conditions (4 
°C in water, black squares; 37 °C in water, red circles; 37 °C in phosphorous buffered saline, cyan 
triangles). 
 
(a) 
(b) 
(c) 
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To demonstrate the utility of CSiQDs for bioimaging, they were incubated with macrophages and then 
imaged. Macrophages, RAW264.7, were prepared in Dulbecco minimum essential media (DMEM) with 
10% fetal bovine serum (FBS), 1% penicillin, and 1% amphotericin B. The day before nanoparticle 
treatment, cells were seeded in 35 mm culture dishes. On the treatment day, the cells, at a confluency of 
70-80% in serum-supplemented media, were treated with the nanoparticles at a specific concentration 
(100 μL/ml media of 2.5 μg/mL CSi QD dispersion) for 24 h at 37°C.25 For imaging, the excitation 
wavelength was the shortest wavelength available on the microscope (405 nm). Figure 5 shows that 
CSiQDs have stained the macrophages in these experiments.  
 
 
Figure 5. Laser confocal microscopy images of macrophages labeled by CSiQDs using single photon 
(405 nm) excitation. Fluorescence (left), transmission (center) and overlaid (right) images are shown. 
 
We previously evaluated two-photon excitation of silicon quantum dots in chloroform and water by 
using femtosecond laser pulses with a wavelength of 778nm and pulse duration of approximately 
160fs
26
. There was no appreciable difference in the photoluminescence spectral distributions when 
comparing one- and two-photon excitation of the silicon nanoparticles. Figure 6 shows two-photon 
excited luminescence images of RAW macrophages labeled with CSiQDs. The absorbance of the silicon 
quantum dots that emit at 650 decreases drastically from the UV to the blue range
26
, therefore much 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.7
01
2.
1 
: P
os
te
d 
21
 M
ar
 2
01
2
 12 
brighter images can be expected by using shorter wavelengths than 900nm.   The Two-photon excitation 
is advantageous for in vivo imaging because transmission through tissues is maximized at the near-IR 
wavelengths. The two-photon imaging technique can also be applied for long-term cellular imaging 
instead of single photon excitation, where the longer wavelengths will result in reduced photodamage 
compared to single-photon UV-excited imaging.  
  
 
Figure 6. Laser confocal microscopy images of macrophages labeled by CSiQDs using two photon (900 
nm) excitation. Fluorescence (left), andtransmission (right) images are shown  
 
Conclusion. 
In conclusion, we have demonstrated a new approach for preparing CSiQDs that form stable dispersions 
in aqueous biological media and can be used in single-photon and two-photon excited bioimaging 
applications. The CSiQDs have impressive emission stability over a broad pH range and provided bright 
and clear cellular labeling on macrophages. Two-photon excitation was also demonstrated, increasing 
the potential for use of these CSiQDs for in vivo imaging and long-term continuous cellular imaging 
studies. The excess positive charges from chitosan could be used for electrostatic binding of specific 
targeting agents for bioapplications. 
Experimental Section 
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Materials. Silane (SiH4, Voltaix, electronic grade, 99.999%), hydrofluoric acid (HF, Acros Organic, 
48-51%), nitric acid (HNO3, EMD, 68-70%), undecylenic acid (Acros Organic, 99%), low molecular 
weight chitosan (Aldrich, 75-85% deacetylated), and acetic acid (J. T. Baker, 100%) were used as 
received. Non-luminescent Si nanoparticle powder was obtained by high temperature laser pyrolysis of 
silane gas in an aerosol reactor as reported previously.
27
 The silicon nanoparticles were collected 
without exposure to air and handled in a glove box to prevent surface oxidation. The primary particle 
diameter of the aggregated silicon powder was between 5 and 10 nm. 
Chemical Etching. To obtain photoluminescent SiQDs, a chemical etching procedure developed by 
Hua et al
28
 was adopted to obtain hydrogen terminated silicon quantum dots of the desired 
photoluminescence emission color. First, 300 mg of Si nanoparticles powder was dispersed in 30 mL of 
methanol by sonication. A hydrofluoric acid (HF, 48 wt %) / nitric acid (HNO3, 69 wt %) mixture (10/1, 
v/v, 110 mL total) was prepared for the chemical etching process. The acid mixture was added to the 
Si/methanol dispersion and stirred for about 1-2 minutes depending on the desired luminescence 
emission color. To terminate the etching procedure the mixture was diluted into 400 mL of methanol. 
Luminescent SiQDs were collected using a pressure filter with poly(vinylidene fluoride) (PVDF) 
membrane filter and washed with 750 mL of 1:3 methanol/water mixture to remove any acid residue. 
Finally, SiQDs were rinsed with 50 mL of methanol then transferred into 20 mL of undecylenic acid. 
The etching processes were performed in a nitrogen-filled glove box to reduce SiQD oxidation and 
maintain hydrogen termination after etching. 
Preparation of Carboxyl-Terminated SiQDs. The Si/undecylenic acid mixture was then transferred to 
a reflux system with addition of 20 mL of ethanol. Three freeze-pump-thaw cycles were used to remove 
dissolved oxygen from the mixture before reaction. The Si QD-undecylenic acid mixture was heated to 
78.9
 o
C for three hours with stirring under an inert argon environment. During the reaction, the double 
bond on undecylenic acid reacted with the hydrogen-terminated silicon by hydrosilylation to give a Si-C 
linkage. Upon surface modification, the solution changed from cloudy to clear, qualitatively confirming 
that the modified SiQDs could be stably dispersed in ethanol, as well as most non-polar solvents such as 
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chloroform, hexane and toluene. Excess undecylenic acid was removed by dialysis of the product 
against 3 L of ethanol three times. The product after the dialysis is a dispersion of undecylenic acid 
functionalized SiQDs (Si-und) in ethanol. 
Chitosan Encapsulation. Low molecular weight chitosan (0.01% w/v) was dissolved in 1.5 vol% 
acetic acid to create a stock solution. The encapsulation was carried out by adding 5 mL of 
chitosan/acetic acid solution into 5 mL Si-und/ethanol and stirring overnight. CSiQDs were separated by 
centrifugation at 13.3K RPM for 1 hour, then redispersed in HPLC water and stored in the refrigerator at 
~4 °C. Dialysis against water could be used to remove remaining traces of ethanol or acetic acid. 
Electron Microscopy. The silicon nanoparticles were characterized by transmission electron 
microscopy (TEM, JEOL 2010) before and after encapsulation. Samples were drop-cast from ethanolic 
or aqueous dispersions onto a TEM grid and the water was allowed to evaporate at room temperature. 
Photoluminescence Spectra. Photoluminescence spectra were measured with a Perkin-Elmer LS 50 
fluorescence spectrometer with a 351 nm band-pass filter used to suppress any scattered light from the 
source. The excitation wavelength was 350 nm. The emission cutoff was set to 390 nm for most of the 
PL measurements shown here. The pH of Si QD dispersions was varied by addition of NaOH or HCl.  
Dynamic Light Scattering. The hydrodynamic diameter and zeta potential were measured by dynamic 
light scattering (DLS, BIC, 90 Plus).  
Cellular Imaging. The uptake of CSiQDs into macrophages was confirmed by confocal imaging 
(Leica Microsystems Semiconductor GmbH, Wetzlerm Germany, with single photon laser excitation at 
405nm or two-photon laser excitation at 900 nm). 
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